BioSpace News Archive

Debiopharm (www.debiopharm.com), a Swiss-based, global biopharmaceutical company, aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today announced the first patient dosed of their first-in-human, phase 1/2 study, GaLuCi™.

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its first-quarter 2023 results on Wednesday, May 3, 2023 at 1 p.m. London time (8 a.m. Eastern Time).

AmbioPharm, a worldwide leader in peptide API CDMO services, to host a workshop on sustainable peptide manufacturing at Biologics 2023 taking place in London, UK on March 29, 2023.

Know Labs, Inc., an emerging developer of non-invasive medical diagnostic technology, announced the establishment of a Scientific Advisory Board comprised of distinguished researchers, innovators and experts in medical technology and human health.

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX) today announced its financial results for the twelve months ended December 31, 2022, and other recent developments.

HAGAR announced today promising preliminary data from its clinical study with Professor Ami Navon from the Weizmann Institute of Science for its non invasive glucose monitoring device, GWave.

A recent study by researchers at the University of California at San Diego, found that a bioenergetic wearable device delivering biological information to the body using photons, has positive effects on the physiology of live cell cultures.

Applied DNA Sciences, Inc. announced that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC, has submitted a validation package to the New York State Department of Health in support of approval for a pharmacogenomics assay as a NYSDOH laboratory-developed test.

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense”) announced today that its annual report on Form 20-F, containing audited consolidated financial statements for the year ended December 31, 2022, as filed with the Securities and Exchange Commission, is available through its website (https://www.neurosense-tx.com), and provided a business update.

Javad Sajan, M.D. Pioneered A Multi-Plane Fat Transfer To Breast Technique That Permanently Revolutionizes The Previously Failed Procedure.